Serum miRNAs in women affected by hyperandrogenic polycystic ovary syndrome: the potential role of miR-155 as a biomarker for monitoring the estroprogestinic treatment. (3rd August 2018)

• Record Type: Journal Article
• Authors: Arancio, Walter; Calogero Amato, Marco; Magliozzo, Miriam; Pizzolanti, Giuseppe; Vesco, Rosalia; Giordano, Carla
• Is Part Of: Gynecological endocrinology. Volume 34:Number 8(2018)
• Page Start: 704
• Page End: 708
• Publication Date: 2018-08-03
• Subjects: Polycystic ovary syndrome -- mir-155 -- visceral adipose index -- antiandrogenic therapy -- biomarker; Endocrine gynecology -- Periodicals; Generative organs, Female -- Diseases -- Periodicals; 618.1
• DOI: 10.1080/09513590.2018.1428299
• Languages: English
• ISSNs: 0951-3590

Abstract

Abstract: MicroRNAs can be used as very efficient circulating biomarkers. The role of microRNAs in polycystic ovary syndrome (PCOS) and the effects of antiandrogen therapy on microRNA expression is still not fully understood. A panel of serum microRNAs were retrotranscribed via looped reverse primer transcription specific for each miRNA and quantified via probe specific RT-PCR in 16 Caucasian hyperandrogenic PCOS women selected according to the Rotterdam criteria and in a subset of seven patients after four months of sequential reverse antiandrogenic therapy. All women recruited underwent an oral glucose tolerance test (OGTT) and a baseline total cholesterol, high density lipoproteins cholesterol, triglycerides, AST and ALT dosage. In the follicular phase women were evaluated for total testosterone, Δ4-androstenedione, DHEAS, 17OHpg, FSH, LH, and 17-β-E2. The AUC2hglucose, ISI Matsuda, oral disposition index (DIo) and visceral adipose index (VAI) were also calculated. We suggest that miR-155 might have a role as biomarker in hyperandrogenic PCOS patients to monitor the effect of antiandrogen therapy.